Gout Attack Risk Lowered With Interleukin-1ß Blockade
Inhibition of IL-1ß with canakinumab significantly decreased gout attack risk at all baseline serum uric acid (SUA) levels and without changing SUA levels.
Sitio Web patrocinado por:
Sitio Web patrocinado por:
Inhibition of IL-1ß with canakinumab significantly decreased gout attack risk at all baseline serum uric acid (SUA) levels and without changing SUA levels.
Copyright © 2025, Sociedad Venezolana de Nefrología - RIF: J-30370247-3.
Diseñado por 